A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05588908

Collaborator

(none)

120

Enrollment

Locations

Arms

16.1

Anticipated Duration (Months)

Patients Per Site

2.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the target dose of phase II and to evaluate the safety, tolerability, pharmacokinetics and efficacy of recombinant anti-IL-1β humanized monoclonal antibody injection at different doses in Chinese participants with acute gout.

Condition or Disease	Intervention/Treatment	Phase
Acute Gout	Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib) Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib) Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib) Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II) Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II) Drug: Compound Betamethasone Injection (phase II) Other: Placebo (phase II)	Phase 1/Phase 2

Detailed Description

The phase Ib study is a multi-center, open label, dose escalation study examining the effect of recombinant anti-IL-1β humanized monoclonal antibody injection and to determine the target dose of phase II for the treatment of acute flare in Chinese gout patients in whom non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine are contraindicated, are not tolerated, or do not provide an adequate response. There are 3 dose groups (100 mg、200 mg and 300 mg) in phase Ib and 10 participants in each group.

The phase II study is a dose-ranging, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel-group study examining the effect of 2 dose regimens (200 mg and 300 mg, based on the outcome of phase Ib) of recombinant anti-IL-1β humanized monoclonal antibody injection versus compound betamethasone injection for the treatment of acute flare in Chinese gout patients in whom NSAIDs and/or colchicine are contraindicated, are not tolerated, or do not provide an adequate response. The phase II recommended dose of SSGJ-613 in subjects with acute gouty was determined according to the phase Ib interim analysis results.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

120 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

Actual Study Start Date :

Jun 29, 2022

Anticipated Primary Completion Date :

Sep 1, 2023

Anticipated Study Completion Date :

Nov 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: SSGJ-613 100 mg (phase Ib) Dose Arm 1 (phase Ib): SSGJ-613 100 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.	Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib) 100 mg subcutaneous (s.c) once Other Names: SSGJ-613 100 mg (phase Ib)
Experimental: SSGJ-613 200 mg (phase Ib) Dose Arm 2 (phase Ib): SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.	Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib) 200 mg subcutaneous (s.c) once Other Names: SSGJ-613 200 mg (phase Ib)
Experimental: SSGJ-613 300 mg (phase Ib) Dose Arm 3 (phase Ib): SSGJ-613 300 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh.	Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib) 300 mg subcutaneous (s.c) once Other Names: SSGJ-613 300 mg (phase Ib)
Experimental: SSGJ-613 200 mg (phase II) Dose Arm 4 (phase II): SSGJ-613 200 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.	Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II) one s.c. injection of SSGJ-613 once, on Day 1. Other Names: SSGJ-613 200 mg (phase II)
Experimental: SSGJ-613 300 mg (phase II) Dose Arm 5 (phase II): SSGJ-613 300 mg subcutaneous (s.c) once. The s.c. injection could be administered into the abdomen or thigh. Randomized patients will receive one s.c. injection of SSGJ-613 and placebo matching compound betamethasone injection (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection is recommended to be administered deeply into the gluteal muscle.	Drug: Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II) one s.c. injection of SSGJ-613 once, on Day 1. Other Names: SSGJ-613 300 mg (phase II)
Active Comparator: Compound Betamethasone Injection 1 mL (phase II) Dose Arm 6 (phase II): Compound betamethasone injection 1 mL intramuscularly (i.m) once. The i.m. injection is recommended to be administered deeply into the gluteal muscle. Randomized patients will receive compound betamethasone injection 1 mL i.m. once and placebo matching SSGJ-613 s.c. once, on Day 1.	Drug: Compound Betamethasone Injection (phase II) 1 mL i.m. once on Day 1 Other: Placebo (phase II) Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products. Other Names: PBO

Outcome Measures

Primary Outcome Measures

Phase Ib: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [From baseline through 24 weeks]
To investigate the safety characteristics.
Phase Ib: Incidence and Severity of Abnormalities in Vital Signs/Physical Examinations, Laboratory Examinations and Other Relevant Examinations [From baseline through 24 weeks]
To investigate the safety characteristics.
Phase II: The Change in Pain Intensity in the Target Joint From Baseline to 72 Hours Post Dose as Measured on a 0-100 mm Visual Analog Scale (VAS) [Baseline, at 72 hrs post-dose]
The change in pain intensity from baseline to 72 hours post dose as measured on a 0-100 mm Visual Analog Scale (VAS): 0= no pain and 100= severe pain. Change from baseline = (post-baseline measurement - baseline).

Secondary Outcome Measures

Phase Ib: Pharmacokinetic (PK) Cmax [From baseline through 24 weeks]
PK parameters (Cmax) following single dose.
Phase Ib: Pharmacokinetic (PK) Tmax [From baseline through 24 weeks]
PK parameters (Tmax) following single dose.
Phase Ib: Pharmacokinetic (PK) AUC 0-t [From baseline through 24 weeks]
PK parameters (AUC 0-t) following single dose.
Phase Ib: Pharmacokinetic (PK) AUC 0-∞ [From baseline through 24 weeks]
PK parameters (AUC 0-∞) following single dose.
Phase Ib: Pharmacokinetic (PK) t1/2 [From baseline through 24 weeks]
PK parameters (t1/2) following single dose.
Phase Ib: The Pain Intensity in the Target Joint at 6, 12, 24, 48, 72 Hours, 4, 5, 6, 7 Days, and 4, 8, 12, 16, 20, 24 Weeks Post Dose as Measured on a 0-100 mm Visual Analog Scale (VAS) [At 6, 12, 24, 48, 72 Hours, 4, 5, 6, 7 Days, and 4, 8, 12, 16, 20, 24 Weeks post-dose]
The pain intensity post dose as measured on a 0-100 mm Visual Analog Scale (VAS): 0= no pain and 100= severe pain.
Phase II: The Pain Intensity in the Target Joint at 6, 12, 24, 48, 72 Hours, 4, 5, 6, 7 Days, and 4, 8, 12 Weeks Post Dose as Measured on a 0-100 mm Visual Analog Scale (VAS) [At 6, 12, 24, 48, 72 Hours, 4, 5, 6, 7 Days, and 4, 8, 12 Weeks post-dose]
The pain intensity post dose as measured on a 0-100 mm Visual Analog Scale (VAS): 0= no pain and 100= severe pain.
The Change in Pain Intensity in the Target Joint From Baseline to 6, 12, 24, 48 Hours Post Dose as Measured on a 0-100 mm Visual Analog Scale (VAS) [Baseline, at 6, 12, 24, 48 hrs post-dose]
The change in pain intensity from baseline to 6, 12, 24, 48 hours post dose as measured on a 0-100 mm Visual Analog Scale (VAS): 0= no pain and 100= severe pain. Change from baseline = (post-baseline measurement - baseline).
The Time to At Least 50% Reduction of Baseline Pain Intensity in the Target Joint Within 7 Days after study drug administration [Baseline, within 7 days after study drug administration]
The time to at least 50% reduction in Pain intensity from baseline as measured by Visual Analog Scale (VAS) for each treatment group, is estimated using the Kaplan Meier method. Participants scored their pain intensity in the target joint on a 0-100 mm VAS, ranging from no pain (0) to unbearable pain (100).
The Time to Complete Pain Remission of Baseline Pain Intensity in the Target Joint Within 12 Weeks after study drug administration [Baseline, within 12 weeks after study drug administration]
The time to complete pain remission in Pain intensity from baseline as measured by a 5-point Likert scale for each treatment group, is estimated using the Kaplan Meier method. Participants scored their pain intensity in the target joint on a 5-point Likert scale: None, mild, moderate, severe, extremely severe.
Percentage of Participants Taking Rescue Medication Within 7 Days After Study Drug Administration [7 days after study drug administration]
Participants who had difficulty in tolerating their pain after the 12 and 72 hours post-dose pain assessments were allowed to take rescue medication.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Must be 18 Years to 65 Years, both male and female
Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of acute arthritis of primary gout.
Presence of acute gout flare for no longer than 7 days
Baseline pain intensity > or = to 50 mm on the 0-100 mm VAS
Contraindicated for, intolerant or unresponsive to NSAIDs, colchicine or both

Exclusion Criteria:

Secondary gout (such as gout caused by chemotherapy, transplant gout, etc.)
Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis
Presence of severe renal function impairment
Intolerance of subcutaneous and intramuscular injection
Known presence or suspicion of active or recurrent bacterial, fungal or viral infection at the time of enrollment
History of malignant tumor within 5 years before screening
Live vaccinations within 3 months prior to the start of the study
Use of forbidden therapy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Site 02	Wuhan	Hubei	China	430030
2	Site 03	Linyi	Shandong	China	276100
3	Site 01	Shanghai	Shanghai	China	200040

Sponsors and Collaborators

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Investigators

Principal Investigator: Hejian Zou, MD, Shanghai Huanshan Hospital Fudan University-Rheumatology
Study Director: Qinghong Zhou, MD, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.